ChromaVision Scanner Gets FDA Clearance
- Share via
SAN JUAN CAPISTRANO — ChromaVision Medical Systems Inc. said Tuesday it received clearance from the Food and Drug Administration to market its new microscopic scanner that screens blood for certain malignancies and infections such as chronic leukemia.
The company hopes to gain clearance to market the device for detecting a number of other diseases, said Douglas Harrington, chief executive officer. He said the company could offer a noninvasive test for Down’s syndrome.
The device works by digitally imaging the color differences between cells that have been treated by a laboratory dye. The dyes are engineered to stimulate diseased cells only, by interacting with a protein, or a bacteria not present in normal cells.
“If there are tumor cells there, that have that protein, they will light up,” Harrington said.
The company is a partnership subsidiary of Safeguard Scientifics Inc. Safeguard stock rose 50 cents Tuesday, closing at $29 per share.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
